AAAAAA

   
Results: 1-25 | 26-50 | 51-74
Results: 1-25/74
Relapse alter allogeneic bone marrow transplantation for refractory anemiais increased by shielding lungs and liver during total body irradiation
Authors: Anderson, JE Appelbaum, FR Schoch, G Barnett, T Chauncey, TR Flowers, MED Storb, R
Citation: Je. Anderson et al., Relapse alter allogeneic bone marrow transplantation for refractory anemiais increased by shielding lungs and liver during total body irradiation, BIOL BLOOD, 7(3), 2001, pp. 163-170
Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: The experience in fourcenters
Authors: Storb, R Blume, KG O'Donnell, MR Chauncey, T Forman, SJ Deeg, HJ Hu, WW Appelbaum, FR Doney, K Flowers, MED Sanders, J Leisenring, W
Citation: R. Storb et al., Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: The experience in fourcenters, BIOL BLOOD, 7(1), 2001, pp. 39-44
Who should be transplanted for AML?
Authors: Appelbaum, FR
Citation: Fr. Appelbaum, Who should be transplanted for AML?, LEUKEMIA, 15(4), 2001, pp. 680-682
Comparison of the L10M consolidation regimen to an alternative regimen including escalating methotrexate/L-asparaginase for adult acute lymphoblasticleukemia: a Southwest Oncology Group Study
Authors: Petersdorf, SH Kopecky, KJ Head, DR Boldt, DH Balcerzak, SP Wun, T Roy, V Veith, RW Appelbaum, FR
Citation: Sh. Petersdorf et al., Comparison of the L10M consolidation regimen to an alternative regimen including escalating methotrexate/L-asparaginase for adult acute lymphoblasticleukemia: a Southwest Oncology Group Study, LEUKEMIA, 15(2), 2001, pp. 208-216
Economic analysis of granulocyte colony stimulating factor as adjunct therapy for older patients with acute myelogenous leukemia (AML): Estimates from a Southwest Oncology Group clinical trial
Authors: Bennett, CL Hynes, D Godwin, J Stinson, TJ Golub, RM Appelbaum, FR
Citation: Cl. Bennett et al., Economic analysis of granulocyte colony stimulating factor as adjunct therapy for older patients with acute myelogenous leukemia (AML): Estimates from a Southwest Oncology Group clinical trial, CANCER INV, 19(6), 2001, pp. 603-610
Hematopoietic stern-cell transplantation for treatment-related leukemia ormyelodysplasia
Authors: Witherspoon, RP Deeg, HJ Storer, B Anasetti, C Storb, R Appelbaum, FR
Citation: Rp. Witherspoon et al., Hematopoietic stern-cell transplantation for treatment-related leukemia ormyelodysplasia, J CL ONCOL, 19(8), 2001, pp. 2134-2141
Impact of therapy with chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011
Authors: Morrison, VA Rai, KR Peterson, BL Kolitz, JE Elias, L Appelbaum, FR Hines, JD Shepherd, L Martell, RE Larson, RA Schiffer, CA
Citation: Va. Morrison et al., Impact of therapy with chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011, J CL ONCOL, 19(16), 2001, pp. 3611-3621
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse
Authors: Sievers, EL Larson, RA Stadtmauer, EA Estey, E Lowenberg, B Dombret, H Karanes, C Theobald, M Bennett, JM Sherman, ML Berger, MS Eten, CB Loken, MR van Dongen, JJM Bernstein, ID Appelbaum, FR
Citation: El. Sievers et al., Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse, J CL ONCOL, 19(13), 2001, pp. 3244-3254
Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5)
Authors: Garrido, SM Appelbaum, FR Willman, CL Banker, DE
Citation: Sm. Garrido et al., Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5), EXP HEMATOL, 29(4), 2001, pp. 448-457
Autologous stem cell transplantation for non-Hodgkin's lymphoma: comparison of radiation-based and chemotherapy-only preparative regimens
Authors: Gutierrez-Delgado, F Maloney, DG Press, OW Golden, J Holmberg, LA Maziarz, RT Hooper, H Buckner, CD Appelbaum, FR Bensinger, WI
Citation: F. Gutierrez-delgado et al., Autologous stem cell transplantation for non-Hodgkin's lymphoma: comparison of radiation-based and chemotherapy-only preparative regimens, BONE MAR TR, 28(5), 2001, pp. 455-461
Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in adults 60 years of age and older
Authors: Gopal, AK Gooley, TA Golden, JB Maloney, DG Bensinger, WI Petersdorf, SH Appelbaum, FR Press, OW
Citation: Ak. Gopal et al., Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in adults 60 years of age and older, BONE MAR TR, 27(6), 2001, pp. 593-599
Blasts from elderly acute myeloid leukemia patients are characterized by low levels of culture- and drug-induced apoptosis
Authors: Garrido, SM Cooper, JJ Appelbaum, FR Willman, CL Kopecky, K Banker, DE
Citation: Sm. Garrido et al., Blasts from elderly acute myeloid leukemia patients are characterized by low levels of culture- and drug-induced apoptosis, LEUK RES, 25(1), 2001, pp. 23-32
Perspectives on the future of chronic myeloid leukemia treatment
Authors: Appelbaum, FR
Citation: Fr. Appelbaum, Perspectives on the future of chronic myeloid leukemia treatment, SEM HEMATOL, 38(3), 2001, pp. 35-42
Hematopoietic reconstitution by transplantation of stem cells from bone marrow or blood. Reply
Authors: Bensinger, WI Storer, B Appelbaum, FR
Citation: Wi. Bensinger et al., Hematopoietic reconstitution by transplantation of stem cells from bone marrow or blood. Reply, N ENG J MED, 344(21), 2001, pp. 1641-1642
Stem-cell transplantation for myelofibrosis.
Authors: Deeg, HJ Appelbaum, FR
Citation: Hj. Deeg et Fr. Appelbaum, Stem-cell transplantation for myelofibrosis., N ENG J MED, 344(10), 2001, pp. 775-776
Haematopoietic cell transplantation as immunotherapy
Authors: Appelbaum, FR
Citation: Fr. Appelbaum, Haematopoietic cell transplantation as immunotherapy, NATURE, 411(6835), 2001, pp. 385-389
Gemtuzumab ozogamicin - Viewpoint
Authors: Appelbaum, FR
Citation: Fr. Appelbaum, Gemtuzumab ozogamicin - Viewpoint, DRUGS, 61(9), 2001, pp. 1323-1323
A proposed objective way to assess results of randomized prospective clinical trials with acute graft-versus-host disease as an outcome of interest
Authors: Al-Ghamdi, H Leisenring, W Bensinger, WI Nash, RA Storb, R Appelbaum, FR Martin, PJ
Citation: H. Al-ghamdi et al., A proposed objective way to assess results of randomized prospective clinical trials with acute graft-versus-host disease as an outcome of interest, BR J HAEM, 113(2), 2001, pp. 461-469
Haemopoietic stem cell transplantation for advanced polycythaemia vera or essential thrombocythaemia
Authors: Jurado, M Deeg, HJ Gooley, T Anasetti, C Chauncey, T Flowers, MED Myerson, D Storb, R Appelbaum, FR
Citation: M. Jurado et al., Haemopoietic stem cell transplantation for advanced polycythaemia vera or essential thrombocythaemia, BR J HAEM, 112(2), 2001, pp. 392-396
The significance of bcr-abl molecular detection in chronic myeloid leukemia patients "late," 18 months or more after transplantation
Authors: Radich, JP Gooley, T Bryant, E Chauncey, T Clift, R Beppu, L Edmands, S Flowers, MED Kerkof, K Nelson, R Appelbaum, FR
Citation: Jp. Radich et al., The significance of bcr-abl molecular detection in chronic myeloid leukemia patients "late," 18 months or more after transplantation, BLOOD, 98(6), 2001, pp. 1701-1707
Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin
Authors: Linenberger, ML Hong, T Flowers, D Sievers, EL Gooley, TA Bennett, JM Berger, MS Leopold, LH Appelbaum, FR Bernstein, ID
Citation: Ml. Linenberger et al., Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin, BLOOD, 98(4), 2001, pp. 988-994
Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia withmyelofibrosis
Authors: Anderson, JE Tefferi, A Craig, F Holmberg, L Chauncey, T Appelbaum, FR Guardiola, P Callander, N Freytes, C Gazitt, Y Razvillas, B Deeg, HJ
Citation: Je. Anderson et al., Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia withmyelofibrosis, BLOOD, 98(3), 2001, pp. 586-593
Immunity of patients surviving 20 to 30 years after allogeneic or syngeneic bone marrow transplantation
Authors: Storek, J Joseph, A Espino, G Dawson, MA Douek, DC Sullivan, KM Flowers, MED Martin, P Mathioudakis, G Nash, RA Storb, R Appelbaum, FR Maloney, DG
Citation: J. Storek et al., Immunity of patients surviving 20 to 30 years after allogeneic or syngeneic bone marrow transplantation, BLOOD, 98(13), 2001, pp. 3505-3512
Administration of cyclosporine for 24 months compared with 6 months for prevention of chronic graft-versus-host disease: a prospective randomized clinical trial
Authors: Kansu, E Gooley, T Flowers, MED Anasetti, C Deeg, HJ Nash, RA Sanders, JE Witherspoon, RP Appelbaum, FR Storb, R Martin, PJ
Citation: E. Kansu et al., Administration of cyclosporine for 24 months compared with 6 months for prevention of chronic graft-versus-host disease: a prospective randomized clinical trial, BLOOD, 98(13), 2001, pp. 3868-3870
Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study
Authors: List, AF Kopecky, KJ Willman, CL Head, DR Persons, DL Slovak, ML Dorr, R Karanes, C Hynes, HE Doroshow, JH Shurafa, M Appelbaum, FR
Citation: Af. List et al., Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study, BLOOD, 98(12), 2001, pp. 3212-3220
Risultati: 1-25 | 26-50 | 51-74